Harmony Biosciences Holdings Inc

-1.86 (-3.75%)
Other Pre-Announcement

Harmony Biosciences Reports Q3 Loss Per Share $0.14

Published: 11/12/2020 13:28 GMT
(HRMY) - Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates.
Q3 Revenue $45.6 Million Versus Refinitiv Ibes Estimate of $40.1 Million.
On Track to Initiate Phase 2 Trial in Patients With Prader-willi Syndrome by Year End.
Qtrly Net Loss per Share $0.14.
Q3 Earnings per Share View $-0.05 -- Refinitiv Ibes Data (analyst estimates).